Drug profile · INN
desirudin recombinant
IPRIVASK
desirudin recombinant (IPRIVASK) is a thrombin inhibitor. Route of administration: subcutaneous. Current US regulatory status: approved.
Drug details — desirudin recombinant
- US status
- approved
- Class
- —
- Route
- SUBCUTANEOUS
- Patents
- 0
- Programs
- 0
- Data quality
- 0.84
Quick answer
desirudin recombinant (IPRIVASK) is a thrombin inhibitor. Route of administration: subcutaneous. Current US regulatory status: approved.
Key facts
Mechanism of action
Thrombin inhibitor
Primary target: Prothrombin
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Related & competitor drugs
Frequently asked questions
What is desirudin recombinant?
desirudin recombinant (IPRIVASK) is a thrombin inhibitor. Route of administration: subcutaneous. Current US regulatory status: approved.
What is the brand name for desirudin recombinant?
IPRIVASK is a marketed brand name for desirudin recombinant. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of desirudin recombinant?
desirudin recombinant has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.